Core Insights - Outset Medical, Inc. has announced new research findings from over 1 million Tablo hemodialysis treatments across approximately 750 facilities, highlighting the effectiveness of their technology in reducing the cost and complexity of dialysis [1][5] - The findings will be presented at the American Society of Nephrology's Kidney Week 2025, which is attended by over 12,000 professionals globally, emphasizing the significance of these results in the field of kidney care [2] Group 1: Research Findings - The studies indicate that insourcing dialysis services can elevate the standard of care in hospitals, providing both clinical benefits and significant cost savings [2] - Data from a large hospital in Florida showed a 94% reduction in serious cardiac or respiratory events and a sustained reduction in central-line bloodstream infections over five years [5] - A high nurse retention rate of over 95% and strong staff satisfaction were reported, alongside a strong return on investment within the first two years of operation [5] Group 2: Clinical Effectiveness - Data from 1 million Tablo treatments across more than 600 facilities supports the clinical effectiveness of insourced dialysis in achieving rigorous treatment goals [5] - Over 99% achievement of treatment goals was noted in 10,000 treatments prescribed for more than 23 hours, performed at approximately 150 hospitals, with minimal interruptions [5] Group 3: Technology Overview - The Tablo Hemodialysis System is designed to reduce the cost and complexity of dialysis, integrating water purification and on-demand dialysate production into a single system [6] - The system is FDA-cleared for use in both hospital and home settings, indicating its versatility and broad application [5][6] - Outset Medical aims to redefine kidney care through innovation and a commitment to improving patient and provider outcomes [6]